SCHEMBL23729867

SCHEMBL23729867

O=C(OCCc1ccccc1)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.63
▸ ALB P02768 1/20 0.63
▸ MAOA P21397 1/20 0.63
▸ CNR1 P21554 1/20 0.63
▸ DRD1 P21728 1/20 0.63
▸ OPRD1 P41143 1/20 0.63
▸ PDE4D Q08499 1/20 0.63
▸ PDE3A Q14432 1/20 0.63
▸ ESR1 P03372 1/20 0.45
▸ ESR2 Q92731 1/20 0.45
▸ MAPT P10636 10/20 0.45
▸ TP53 P04637 4/20 0.45
▸ LMNA P02545 4/20 0.45
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23729816 0.91 TTR (0.58) TTRALBMAOACNR1DRD1
SCHEMBL23729866 0.89 TTR (0.65) TTRALBMAOACNR1DRD1
SCHEMBL23729820 0.89 TTR (0.54) TTRALBMAOACNR1DRD1
SCHEMBL23729838 0.86 TTR (0.55) TTRALBMAOACNR1DRD1
SCHEMBL30163325 0.86 TTR (0.66) TTRALBMAOACNR1DRD1
SCHEMBL24928492 0.86 TTR (0.66) TTRALBMAOACNR1DRD1
SCHEMBL23729817 0.85 TTR (0.56) TTRALBMAOACNR1DRD1
SCHEMBL23704478 0.85 TTR (0.65) TTRALBMAOACNR1DRD1
SCHEMBL24928448 0.84 TTR (0.63) TTRALBMAOACNR1DRD1
SCHEMBL30163134 0.84 TTR (0.63) TTRALBMAOACNR1DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 — — US disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 — — US disclosed
WO-2021154842-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. (US) 2021-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING TTR, TTPA, TNNC1 TTR 1/4885ALB 8/4885MAOA 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback